Another Big Pharma Embraces AI As Exscientia Bags GSK
Executive Summary
GSK's deal with Exscientia will see the Scottish artificial intelligence pioneer discover new small molecules against targets selected by the big pharma. Exscientia is already working with Sanofi, Evotec, Sumitomo Dainippon Pharma and Sunovion across a range of disease areas, and is in talks with others.
You may also be interested in...
Evotec Invests €15m In AI-driven Exscientia
Evotec has deepened its relationship with artificial intelligence company Exscientia by investing €15m in the UK-based company; the CRO wants to build on the pair's existing collaboration in immuno-oncology and use its stake to diversify the AI firm's portfolio.
Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
Quest To Use AI In Drug Discovery Joins Sanofi and Exscientia
Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.